Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Johnson & Johnson's daratumumab wins European approval for self-administration in multiple myeloma and related conditions
Antibody, cancer, monoclonal antibody, multiple myeloma, CD38 target - Read more

FDA approves Biogen's high-dose Spinraza (nusinersen) antisense oligonucleotide targeting SMN2 for spinal muscular atrophy treatment
Antisense oligonucleotide, neurological, spinal muscular atrophy, SMN protein, high-dose formulation - Read more

Royalty Pharma, Johnson & Johnson co-fund autoimmune antibody JNJ-4804 development with $500M investment
Royalty agreement, autoimmune, antibody, milestone payments - Read more

AbClon, Chong Kun Dang Pharmaceutical expand partnership developing bispecific antibodies for solid tumors using AffiMab platform
Co-development, oncology, bispecific antibodies, drug discovery - Read more

Sam Chun Dang Pharm licenses semaglutide generics to undisclosed partner, $100M milestones, 90% profit share
Licensing deal, semaglutide generics, milestone payments, profit sharing - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

United Therapeutics' nebulised Tyvaso (treprostinil) hits Ph3 primary endpoint in idiopathic pulmonary fibrosis
Small molecule, respiratory disease, prostacyclin mimetic, idiopathic pulmonary fibrosis, nebulized formulation - Read more

Connect Biopharma's rademikibart (IL-4/IL-13 blocker) shows positive Ph3 results for atopic dermatitis treatment
Antibody, autoimmune, monoclonal antibody, atopic dermatitis, IL-4/IL-13 inhibitor - Read more

Idorsia's Quviviq (daridorexant) shows Ph2 success in pediatric insomnia targeting dual orexin receptors
Small molecule, neurological, dual orexin receptor antagonist, pediatric insomnia, neurodevelopmental disorders - Read more

Tanabe Pharma prepares FDA submission for dersimelagon (MT-7117) targeting erythropoietic protoporphyria following Ph3 success
Small molecule, rare disease, melanocortin-1 receptor agonist, erythropoietic protoporphyria, dermatology - Read more

Merck & Co.'s oral enlicitide decanoate (MK-0616) shows 64.6% LDL cholesterol reduction in Ph3 hypercholesterolemia trial
Small molecule, cardiovascular, PCSK9 inhibitor, hypercholesterolemia, LDL cholesterol lowering, combination therapy - Read more

Simcere Pharmaceutical's rademikibart achieves 96.6% EASI-75 response in Ph3 atopic dermatitis trial at 52 weeks
Monoclonal antibody, autoimmune, atopic dermatitis, rademikibart, EASI-75 response - Read more

Palisade Bio reports positive Ph1b results for PALI-2108 PDE4 inhibitor in fibrostenotic Crohn's disease
Small molecule, autoimmune, PDE4 inhibitor, Crohn's disease, prodrug, targeted delivery - Read more

Hengrui Pharma and Braveheart Bio report positive Ph2 results for HRS-1893 cardiac myosin inhibitor in obstructive hypertrophic cardiomyopathy
Small molecule, cardiovascular, cardiac myosin inhibitor, obstructive hypertrophic cardiomyopathy - Read more

Viridian Therapeutics' elegrobart (VRDN 003) meets Ph3 primary endpoint targeting IGF-1R for thyroid-eye disease treatment
Monoclonal antibody, autoimmune, thyroid eye disease, IGF-1R target, subcutaneous injection - Read more

Sanofi's amlitelimab meets Ph3 endpoints for moderate-to-severe atopic dermatitis despite mixed results and safety concerns
Antibody, autoimmune, monoclonal antibody, atopic dermatitis, OX40L target, safety concerns - Read more

Kailera Therapeutics plans IPO, obesity drugmaker with experimental weight loss medicines
Obesity, GLP-1 agonist, clinical-stage, combination therapy - Read more

Blackstone closes $6.3B fund for life sciences investing and partnerships
Private equity, life sciences investing, platform technology, royalty financing - Read more

Stratum Biosciences raises $2M Seed, AI-powered dermatology discovery platform development
AI/ML platform, dermatology, biomarker discovery, platform technology - Read more

Oncomatrix raises $67M funding, developing Quantum ADCs against tumor microenvironment
Oncology, antibody-drug conjugates, tumor microenvironment, clinical-stage - Read more

Aurinia Pharmaceuticals to acquire Kezar Life Sciences for $51M, gaining access to beleaguered hepatitis asset zetomipzomib
Immunoproteasome inhibitor, autoimmune, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Astellas Pharma terminates Ph1 trial of ASP5502 (STING inhibitor) for Sjögren's syndrome treatment
Small molecule, autoimmune, STING inhibitor, Sjögren's syndrome - Read more

Takeda restructuring affects 634 US employees, expected to save $1.25B by fiscal 2028
Small molecule, autoimmune, cost reduction, operational, strategic - Read more

FDA issues untitled letters to BMS, Novartis, Gilead, Iovance over misleading biologics promotional materials
CAR-T, oncology, regulatory, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here